Fabry Disease Market Analysis Through 2030: Market Size, Growth Trends And Industry Outlook
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Fabry Disease Market Size, Value And Growth Trajectory Through 2030
The Fabry disease market has experienced robust expansion in recent years. It is projected to increase from $2.26 billion in 2025 to $2.43 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.7%. Historically, this market growth can be attributed to heightened awareness of rare genetic disorders, the approval of enzyme replacement therapies, the expansion of specialty clinics, the growth in genetic screening programs, and rising diagnosis rates.
The Fabry disease market is projected to undergo significant expansion in the coming years, with its size expected to reach $3.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is primarily driven by advancements in gene-based therapies, the broadening of newborn screening initiatives, increased healthcare investment in rare diseases, the evolution of personalized medicine, and the creation of next-generation oral therapies. Significant trends influencing this period include the rising adoption of enzyme replacement therapy, a heightened emphasis on diagnosing rare diseases, the growing application of genetic testing for early detection, the expansion of oral and adjunct treatment options, and the increasing implementation of patient-centric treatment approaches.
Get A Free Sample Report With In-Depth Market Insights:
Fabry Disease Market Demand Drivers: What’s Powering Industry Growth?
An increasing emphasis on personalized medicine is anticipated to fuel the expansion of the fabry disease market in the future. This treatment approach utilizes an individual’s genetic, environmental, and lifestyle data to customize medical care and therapies, aiming for improved patient results. The heightened attention on personalized medicine stems from its capacity to enhance treatment efficacy and mitigate adverse effects through the customization of therapies for specific patient requirements. It facilitates the customization of treatment strategies according to a patient’s particular genetic mutation and the seriousness of their disease, thereby bettering outcomes and reducing unwarranted side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Consequently, an increasing focus on personalized medicine is a key driver for the growth of the fabry disease market.
Fabry Disease Market Segmentation And Category Overview
The fabry disease market covered in this report is segmented –
1) By Type: Type 1, Type 2, Other Types
2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments
3) By Diagnosis: Blood Test, Genetic Test, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease
2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease
3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease
Fabry Disease Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies in the fabry disease market are concentrating on creating novel therapies, such as PEGylated enzyme replacement therapy (ERT). This focus aims to boost treatment effectiveness, improve patient adherence, and decrease immunogenic reactions often seen with traditional ERTs. PEGylated enzyme replacement therapy (ERT) represents an altered version of standard ERT, where polyethylene glycol (PEG) chains are joined to the enzyme. This modification serves to elevate its stability, extend its circulation duration within the body, and diminish reactions from the immune system. An illustrative example is the announcement in May 2023 by Chiesi Global Rare Diseases, a division of the Italy-based pharmaceutical company Chiesi Group, regarding the U.S. Food and Drug Administration (FDA), a US-based government agency, granting approval for PRX-102 (pegunigalsidase alfa) for treating adult Fabry disease patients. This approval stems from a comprehensive clinical program involving more than 140 patients, with long-term monitoring spanning up to 7.5 years. The program conclusively showed the therapy’s capability in lessening renal Gb3 deposits and sustaining kidney function, all while demonstrating a favorable safety profile.
Fabry Disease Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH
View The Full Fabry Disease Market Report:
Fabry Disease Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the fabry disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
